Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
Dae-Hwan Nam1,2, Jinsook Park3, Sun-Hyun Park1, Ki-Suk Kim1,4,*, and Eun Bok Baek3,*
1Predictive Model Research Center, Korea Institute of Toxicology, Daejeon 34114, Korea, 2Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA, 3Corporate R&D, LG Chem, Ltd., Daejeon 34122, 4Department of Human and Environmental Toxicology, University of Science and Technology, Daejeon 34113, Korea
Received: April 16, 2019; Revised: July 23, 2019; Accepted: July 24, 2019
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetes is associated with an increased risk of cardiovascular complications. Dipeptidyl peptidase-4 (DPP-IV) inhibitors are used clinically to reduce high blood glucose levels as an antidiabetic agent. However, the effect of the DPP-IV inhibitor gemigliptin on ischemia/reperfusion (I/R)-induced myocardial injury and hypertension is unknown. In this study, we assessed the effects and mechanisms of gemigliptin in rat models of myocardial I/R injury and spontaneous hypertension. Gemigliptin (20 and 100 mg/kg/d) or vehicle was administered intragastrically to Sprague–Dawley rats for 4 weeks before induction of I/R injury. Gemigliptin exerted a preventive effect on I/R injury by improving hemodynamic function and reducing infarct size compared to the vehicle control group. Moreover, administration of gemigliptin (0.03% and 0.15%) powder in food for 4 weeks reversed hypertrophy and improved diastolic function in spontaneously hypertensive rats. We report here a novel effect of the gemigliptin on I/R injury and hypertension.